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Abstract
Background: Seizures are common in juvenile Huntington’s disease (HD), but considered to be rare in adult-
onset HD. We studied the occurrence of epilepsy and seizures in a nationwide cohort of Finnish patients with
adult-onset HD.
Methods: Patients with HD and their diagnoses of epilepsy or seizures were identified by a search into a
nationwide registry. Cases were verified in a subsequent review of patient charts.
Results: Three out of 114 HD patients alive on prevalence date had been diagnosed with epilepsy giving
a prevalence of 2.6 % (95 % CI, 0.6–7.5). In addition, one patient with a single unprovoked seizure, one patient with
a medication-induced seizure and two patients with transient nonspecific attacks were identified. Epilepsy was not
associated with clinical severity of HD and seizures were controlled with antiepileptic medications (AEDs). Generalized
tonic-clonic seizures (GTCs) were the most common seizure type.
Conclusions: Prevalence of epilepsy is similar in patients with adult-onset HD compared to general population.
Seizures are easily controlled with AEDs.
Keywords: Antiepileptic drug therapy, Clinical neurology, Epileptic seizures, Huntington’s disease, Neurodegenerative
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Background
Epileptic seizures are common in juvenile-onset Hun-
tington’s disease (HD), where they occur at a frequency
of 38 % [1]. The seizures are most often of the general-
ized tonic-clonic (GTC) type followed by tonic, myo-
clonic and staring spells [1–3]. On the other hand,
seizures are thought to be rare in adult-onset HD and,
even more, it has been proposed that the clinical diagno-
sis of HD should be re-evaluated, if seizures occur in an
adult patient [4]. However, research on the subject is
scarce, as the occurrence of seizures and epilepsy in
adult-onset HD has not been thoroughly investigated
since the introduction of genetic testing for HD in
1993. We examined the incidence of epilepsy and
seizures in a nationwide cohort of Finnish patients
with adult-onset HD.
Methods
We have recently reported on the ascertainment of a na-
tional cohort of patients with HD through a search in
the Finnish Care Register for Health Care and outpatient
benchmarking database [5]. These registries are main-
tained by the National Institute of Health and Welfare
(THL) and cover all public hospitals and health centers
in Finland. Patients treated for adult-onset HD between
the years 1987–2010 were identified (N = 206, of whom
162 were genetically confirmed) and their patient charts
were reviewed for clinical and genetic information. The
mean age at HD diagnosis was 53.2 years and the mean
age at death was 60.9 years (N = 104). The median
follow-up since HD diagnosis was 7.6 years (range 0.6–
23.8 years) and mean age at the end of follow-up was
61.2 years (range 28.0–86.0 years). On the prevalence
date (31 December, 2010) 114 patients were alive.
The two THL registries were then searched for the
seizure-designated codes R56.8 and G40-G42 among the
206 HD patients and their clinical charts were reviewed
by JS. Patients were deemed to be eligible, if the
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attending neurologist had made the diagnosis of epilepsy
or epileptic seizure. Active epilepsy was defined as a
patient with epilepsy having had seizures during the last
5 years. All the cases with seizures identified in the data-
base search could be confirmed in the chart review and,
in addition, no non-coded cases were encountered. The
study was approved by the ethics committee of the
Hospital District of Southwest Finland (19/180/2010)




Four patients had been diagnosed with epilepsy. One of
these patients had only experienced one seizure and was
not considered to have epilepsy in this study. For the
three remaining patients, the median age at HD diagno-
sis was 49 years (range, 35–76 years), which did not dif-
fer from that in patients without epilepsy (52 years;
range, 23–82 years) (p = 0.89, Mann–Whitney U test).
The prevalence of diagnosed epilepsy among living HD
patients on the prevalence date was 2.6 % (95 % confi-
dence interval 0.6–7.5 %) and the prevalence of active
epilepsy was 0.9 % (95 % CI 0.0–4.8 %). The crude inci-
dence of epilepsy was 24/100,000 person-years.
Patient I
Patient I presented with three episodes of impaired con-
sciousness considered epileptiform at the age of 56 years
(Table 1). EEG and brain CT were normal. He was diag-
nosed with temporal lobe epilepsy and carbamazepine
(CBZ) resulted in complete seizure control. Later CBZ
was switched to phenytoin (PHT), but the reason for this
change was not documented. HD was diagnosed at the
age of 76 years on the basis of balance impairment, dys-
kinesias and chorea. He had no family history of HD,
but his father had exhibited similar motor symptoms late
in life. PHT was discontinued after a 20-year seizure-
free period and no new seizures occurred during the 9
years of follow-up.
Patient II
Patient II had presented with seizures in the course of
an appendicitis at the age of 11 years and in association
with alcohol use at the age of 20 years. At the age of
33 years an unprovoked GTC occurred followed by ag-
gressive behavior for half an hour before returning to
normal consciousness. EEG revealed an irritative pattern
in the form of irregular intermediate velocity complexes
with sharp waves on the left and short paroxysms after
hyperventilation. Brain CT showed local atrophy in the
right temporal region, which was considered a possible
sequel of a childhood trauma. Slow-release CBZ resulted
in complete seizure control. Withdrawal of CBZ was
attempted twice after a 10-year seizure-free period and a
normal EEG. Seizures recurred on both occasions, but
were again well controlled after reinstitution of CBZ. No
new clinical seizure activity occurred during the 11 years
of follow-up after the second reinstitution of CBZ at the
age of 47 years.
At the age of 49 years the patient was evaluated be-
cause of cognitive and behavioral problems. Marked
hyperkinesia, clumsiness, impairment of saccade initi-
ation and motor impersistence along with poor insight
suggested the diagnosis of HD. Indeed, his grandmother,
mother, maternal uncle and aunt had been diagnosed
with HD and the patient also received the diagnosis.
However, genetic testing was never performed. The pa-
tient was institutionalized at the age of 54 years because
of progression of HD.
Patient III
Patient III was diagnosed with HD at the age of 35 years
on the basis of depression, clumsiness, cognitive deteri-
oration, chorea and a family history of HD. At the age of
40 years she presented with an attack during which she
gasped, drooled and was unresponsive though her eyes
were open. There were no tonic-clonic movements. The
attack occurred in the morning before waking up and
lasted for 15 min. Afterwards she was oriented but had
no recollection of the events. EEG revealed several iso-
lated spike-wave discharges over the convexity, some of
which were associated with muscle jerks. Unspecified
epilepsy was diagnosed, but no AED was instituted. Four
months later she was admitted because of worsening of
startle-type muscle spasms. Slow-release valproic acid
was initiated resulting in significant improvement. The
patient did not attend follow-up visits.
Table 1 Characteristics of Finnish Huntington’s disease patients with epileptic seizures
Repeat length Age (years) at
Patient Gender Inheritance CAG (affected) CAG (wild type) HD diagnosis Seizure
onset
Medication Tapering off Age at death
I Male Paternal 40 19 76 56 CBZ, later PHT Successful 85
II Male Maternal n.d. n.d. 49 33 CBZ 2 Attempts, unsuccessful
III Female Maternal 44 17 35 40 VPA n.a.
n.a. not attempted, n.d. not determined, CBZ Carbamazepin, PHT Phenytoin, VPA Valproic acid
Sipilä et al. BMC Neurology  (2016) 16:24 Page 2 of 4
Patients with seizures and nonspecific paroxysmal
symptoms
A woman, aged 32 years, experienced a tonic-clonic seiz-
ure. Slow-release CBZ was initiated and no further
seizures were recorded during the 9 years of follow-up.
In the year following the GTC, she was diagnosed with
HD, the symptoms of which had begun at the age of
21 years. Another woman, aged 56 years, experienced
one tonic-clonic seizure followed by transient decrease
in blood pressure 10 years after she had received the
diagnosis of HD. At the time of the seizure, she was
being treated for respiratory tract infection with clari-
thromycin, which was assumed to have increased the
blood concentration of clozapine. Blood levels were not
measured. Clarithromycin was discontinued and seizures
did not recur in 5 years of follow-up despite the use of
clozapine.
Two other patients (one man) reported repeated short
spells of decreased awareness and attention including
memory disruption. Their EEG studies revealed no
pathological findings. Valproic acid was initiated for the
male patient, but no change in the attack frequency was
evident when on or off the medication. No diagnosis of
epilepsy was confirmed and the attacks abated within 3
years in both cases.
Discussion
We found that the point prevalence of diagnosed epi-
lepsy in our cohort of adult-onset HD patients was 2.6 %
(95 % CI 0.6–7.5 %). The prevalence of active epilepsy
was 0.9 % (95 % CI 0.0–4.8 %), which is rather similar to
the prevalence of 0.6 % (95 % CI 0.61–0.65 %) reported
for the Finnish general adult population [6].
The phenotype of adult-onset HD differs markedly
from that of juvenile HD [2, 3, 7]. Seizures are a well-
established part of juvenile HD [1–3] but rare in
adult-onset HD [4]. Our results support this view.
The available information is not sufficient to explain the
higher seizure susceptibility in juvenile HD compared to
that in the adult-onset disease [8], but it is important to
note the marked inverse association between seizure risk
and age of onset in juvenile HD [1, 2, 9]. A literature sur-
vey performed prior to the introduction of genetic testing
for HD has revealed that 90 % of patients have seizures, if
the onset of HD is before 5 years of age. This proportion
decreases to 52 % among patients with age of onset
between 11 and 20 years [9]. Furthermore, it has been
reported that the mean age of HD onset is 5 years lower
in juvenile HD patients with seizures than that in patients
without seizures [1] and that only those with disease onset
younger than 10 years develop seizures [2].
Although the Finnish Care Registers have been found
to be reliable [10], the retrospective setting of the study
entails that we may have missed cases with seizures. The
generalizability of our results may also be limited by the
fact that prevalence of HD in Finns is lower than that in
many other European populations [5, 11].
Conclusions
Our findings suggested that, contrary to juvenile HD,
epilepsy is an infrequent and easily controlled co-
morbidity in adult-onset HD. GTC was the seizure type
most often observed in our patients. Our adult-onset
patients responded uniformly well to medication and
seizure freedom was achieved with the first AED pre-
scribed. We found no difference in the prevalence of
epilepsy when comparing patients with adult-onset HD
to general population.
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